A 2x blend tesamorelin 10mg ipamorelin 5mg kit contains two vials pairing a GHRH analog with a ghrelin mimetic. Learn dosing math, reconstitution, and safety.
A 2x blend tesamorelin 10mg ipamorelin 5mg is a two-vial research kit in which each vial holds 10 mg of tesamorelin and 5 mg of ipamorelin, for 20 mg and 10 mg total across the pair. Both peptides sit in a single lyophilized powder at a fixed 2:1 ratio, so any dose drawn from the vial delivers both compounds at once. No regulatory agency has approved this combination for human use, and it is sold as a laboratory reference material.
What the 2x Label Actually Means
"2x" is a packaging term, not a potency claim. It tells you the listing ships two identical vials instead of one, doubling the total peptide in the kit. Each vial stays self-contained, so you reconstitute and draw from one at a time.
| Component | Per vial | 2-vial kit total | Ratio |
|---|---|---|---|
| Tesamorelin | 10 mg | 20 mg | 2 parts |
| Ipamorelin | 5 mg | 10 mg | 1 part |
| Total peptide | 15 mg | 30 mg | 2:1 |
Why Tesamorelin and Ipamorelin Are Studied Together
Tesamorelin and ipamorelin act on different receptors that feed the same downstream pathway: growth hormone release from the pituitary.
- Tesamorelin is a stabilized growth hormone-releasing hormone (GHRH) analog. It binds GHRH receptors on somatotroph cells and raised both GH and IGF-1 in human trials.
- Ipamorelin is a pentapeptide ghrelin-receptor (GHS-R1a) agonist. In animal and early human work it stimulated GH release with comparatively small effects on cortisol and prolactin.
Because GHRH and ghrelin signaling are complementary, researchers often test them together to see whether GH pulses are larger or longer-lasting than with either peptide alone. That overlap is the entire rationale for a combined vial.
Reconstitution Math for a 10mg/5mg Vial
Each vial contains 15 mg of total peptide, and the volume of bacteriostatic water you add sets the concentration. The 2:1 ratio holds no matter which volume you choose.
| BAC water added | Total concentration | Tesamorelin per 0.1 mL | Ipamorelin per 0.1 mL |
|---|---|---|---|
| 1 mL | 15 mg/mL | 1,000 mcg | 500 mcg |
| 2 mL | 7.5 mg/mL | 500 mcg | 250 mcg |
| 3 mL | 5 mg/mL | 333 mcg | 167 mcg |
| 5 mL | 3 mg/mL | 200 mcg | 100 mcg |
A 2 mL reconstitution is popular because the numbers stay simple: 0.1 mL, or 10 units on a U-100 insulin syringe, delivers 750 mcg of total peptide split as 500 mcg tesamorelin and 250 mcg ipamorelin. The same arithmetic applies to the tesamorelin/ipamorelin 12 2mg reconstitution instructions you may see for larger-format vials.
Typical Research Dose Ranges and the Ratio Problem
Published human data on these two peptides were generated with the compounds used separately, and that matters when you evaluate a fixed blend.
- Tesamorelin was studied at 1 mg and 2 mg once daily by subcutaneous injection in trials of visceral fat in people with HIV-associated lipodystrophy.
- Ipamorelin was explored at roughly 100 to 300 mcg per administration in early human studies.
At a 2:1 ratio, a dose that supplies 2 mg of tesamorelin also supplies 1 mg of ipamorelin, which is several times the amount used in most ipamorelin research. Researchers who want the two peptides at independent doses typically buy them as separate vials rather than a blend.
A fixed 2:1 blend makes it impossible to adjust the tesamorelin and ipamorelin amounts independently.
How This Blend Compares With Other Peptide Stacks
Ratio and half-life are the two features that separate one blend from another. The table below shows where a 10mg/5mg tesamorelin-ipamorelin kit sits.
| Blend | Typical ratio | Primary research focus |
|---|---|---|
| Tesamorelin 10 mg / ipamorelin 5 mg | 2:1 | GHRH plus ghrelin-receptor GH release |
| CJC-1295 without DAC 5 mg / ipamorelin 5 mg | 1:1 | GHRH plus ghrelin-receptor GH release |
| Fragment 176-191 / CJC-1295 / ipamorelin | Varies | Lipolysis signaling plus GH release |
| AOD-9604 plus tesamorelin | Varies | HGH fragment region plus a GHRH analog |
When researchers weigh cjc-1295 ipamorelin vs tesamorelin, the practical difference is half-life and dosing frequency: CJC-1295 with DAC is long-acting, while tesamorelin and ipamorelin are short-acting and usually discussed as daily or multiple-daily injections. A cjc-1295 without dac 5mg ipamorelin 5mg vial is a 1:1 blend with a different ratio and a different injection rhythm.
Some configurations step outside GH release entirely. A fragment 176-191 & cjc-1295 & ipamorelin blend targets lipolysis signaling alongside GH, and aod 9604 with tesamorelin pairs the HGH fragment region with a GHRH analog. Those answer different research questions than a straightforward 2:1 GH blend does.
Storage, Handling, and Safety Considerations
- Store lyophilized vials refrigerated at 2 to 8 degrees Celsius or frozen at -20 degrees Celsius, protected from light.
- Swirl gently instead of shaking, since foaming can damage peptide structure.
- Refrigerate after reconstitution and follow the vendor's stability window, which is usually measured in weeks.
Tesamorelin is FDA-approved as Egrifta for HIV-associated lipodystrophy, but that approval covers the single agent, not a tesamorelin-ipamorelin combination. Ipamorelin has no FDA approval for human use, and blended research vials are not manufactured under pharmaceutical GMP for human consumption.
Reported effects in human tesamorelin trials included injection-site reactions, joint pain, peripheral edema, and changes in blood glucose. Because these products are sold for research use only, dosing questions belong with a licensed healthcare professional rather than a vendor's product page.
RELATED PEPTIDE TOPICresearch peptide IpamorelinFrequently Asked Questions
How much bacteriostatic water do I add to a tesamorelin 10mg / ipamorelin 5mg vial?
There is no single required volume, but 2 mL is the most common choice because it produces clean numbers. With 2 mL added to 15 mg of total peptide, the concentration is 7.5 mg/mL and a 0.1 mL draw yields 500 mcg tesamorelin plus 250 mcg ipamorelin. Adding 1 mL doubles that concentration, while 3 mL or 5 mL lowers it proportionally.
Is a tesamorelin and ipamorelin blend FDA approved?
No. Tesamorelin itself is FDA-approved as Egrifta for HIV-associated lipodystrophy, but that approval covers the single product, not a combination with ipamorelin. Ipamorelin has no FDA approval for human use in any form. Blended vials of tesamorelin and ipamorelin are sold as research chemicals for laboratory use only.
Can I dose tesamorelin and ipamorelin separately with a blended vial?
No, not really. A blended vial locks the two peptides at a fixed 2:1 ratio, so any change in volume moves both compounds at once. Because tesamorelin research doses are measured in milligrams and ipamorelin doses in micrograms, that ratio pushes ipamorelin well above typical research amounts. Researchers who need independent dosing usually purchase the two peptides in separate vials.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.